Skip to main content
. 2021 Jul 8;3(9):e627–e637. doi: 10.1016/S2665-9913(21)00212-5

Figure 3.

Figure 3

Functional humoral immunogenicity of the COVID-19 vaccine BNT162b2

(A) Neutralisation titres against wild-type SARS-CoV-2 on day 28 after the first dose of BNT162b2. (B) Neutralisation titres against B.1.1.7 SARS-CoV-2 variant on day 28 after the first dose of BNT162b2. The circles represent individual values. The red diamonds and range lines indicate the median and IQR. In the IL-23 inhibitor group, filled circles represent participants receiving IL-23p19 inhibitors and hollow circles represent participants receiving an IL-12/23p40 inhibitor. The horizontal dashed line indicates neutralisation activity threshold. (C) Correlation between spike-specific IgG and neutralisation titres against wild-type or the B.1.1.7 variant. Blue diamonds show individual patients, shading indicates the 95% CI. EC50=half maximal effective concentration. ID50=50% inhibitory dilution. IL=interleukin. TNF=tumour necrosis factor.